# RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

> **NCT01149356** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 15 (actual)

## Conditions studied

- Estrogen Receptor Positive
- HER2/Neu Negative
- Male Breast Carcinoma
- Recurrent Breast Carcinoma
- Stage IIIB Breast Cancer
- Stage IIIC Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** Exemestane
- **DRUG:** Gamma-Secretase Inhibitor RO4929097
- **DRUG:** Goserelin Acetate

## Key facts

- **NCT ID:** NCT01149356
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2012-12
- **Final completion:** 2013-04
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Manufacturer discontinued drug development.
- **Last updated:** 2015-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149356, "RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01149356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*